Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at Cantor Fitzgerald lifted their FY2023 earnings per share estimates for shares of Solid Biosciences in a research report issued on Tuesday, November 14th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings per share of ($4.98) for the year, up from their prior forecast of ($5.39). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($4.88) per share. Cantor Fitzgerald also issued estimates for Solid Biosciences’ FY2024 earnings at ($3.63) EPS.
Solid Biosciences Price Performance
Solid Biosciences stock opened at $2.57 on Friday. The company has a current ratio of 9.38, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $2.50 and a 200 day moving average price of $4.16. Solid Biosciences has a 12-month low of $1.81 and a 12-month high of $8.20. The stock has a market cap of $51.85 million, a P/E ratio of -0.57 and a beta of 1.33.
Institutional Trading of Solid Biosciences
About Solid Biosciences
Solid Biosciences Inc, a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases.
- Five stocks we like better than Solid Biosciences
- Best Aerospace Stocks Investing
- 3 large caps with red hot RSIs with upside
- 3 Fintech Stocks With Good 2021 Prospects
- Johnson Controls International: Nothing but upside for investors
- What Are Dividend Challengers?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.